Does ENCORAFENIB Cause Hepatic cytolysis? 40 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 40 reports of Hepatic cytolysis have been filed in association with ENCORAFENIB (BRAFTOVI). This represents 0.5% of all adverse event reports for ENCORAFENIB.
40
Reports of Hepatic cytolysis with ENCORAFENIB
0.5%
of all ENCORAFENIB reports
0
Deaths
21
Hospitalizations
How Dangerous Is Hepatic cytolysis From ENCORAFENIB?
Of the 40 reports, 21 (52.5%) required hospitalization, and 2 (5.0%) were considered life-threatening.
Is Hepatic cytolysis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ENCORAFENIB. However, 40 reports have been filed with the FAERS database.
What Other Side Effects Does ENCORAFENIB Cause?
Death (1,004)
Off label use (989)
Nausea (758)
Fatigue (685)
Diarrhoea (574)
Neoplasm progression (548)
Pyrexia (539)
Product use in unapproved indication (506)
Vomiting (429)
Rash (414)
What Other Drugs Cause Hepatic cytolysis?
ACETAMINOPHEN (1,469)
ATORVASTATIN (681)
PEMBROLIZUMAB (601)
CARBOPLATIN (577)
METHOTREXATE (468)
SULFAMETHOXAZOLE\TRIMETHOPRIM (356)
PACLITAXEL (324)
ENOXAPARIN (307)
AMOXICILLIN (273)
VALACYCLOVIR (261)
Which ENCORAFENIB Alternatives Have Lower Hepatic cytolysis Risk?
ENCORAFENIB vs ENDOXAN
ENCORAFENIB vs ENDOXAN BAXTER
ENCORAFENIB vs ENDOXAN INJ
ENCORAFENIB vs ENDOXAN , POUDRE POUR
ENCORAFENIB vs ENFORTUMAB VEDOTIN